CNS Pharmaceuticals, Inc. (CNSP) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.7x

Market Cap

$8.36M

MomentumView details →

1D Return

−2.83%

YTD Return

+10.92%

RSI (14)

54.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.7x

Market Cap

$8.36M

RSI (14)

54.5

MomentumView details →

1D Return

−2.83%

YTD Return

+10.92%

SummaryUpdated Jun 1, 2026

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Houston, Texas. The company went public in November 2019 and focuses exclusively on developing novel anti-cancer drug candidates for treating brain and central nervous system tumors, one of the most challenging areas in oncology. CNS Pharmaceuticals operates as a development-stage company with no commercial products yet approved for sale.

Ask drillr about CNS Pharmaceuticals, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−91.75%

ROA (TTM)

−76.12%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+88.43%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+92.34%

EBITDA YoY

−7.84%

EarningsView details →

EPS (Actual)

−$0.38

EPS Surprise

−58.33%

Beats (12Q)

5/12

Next Q EPS Est

−$0.27

Avg Surprise (4Q)

−42.54%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.86x

Quick Ratio

5.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−16.70M

Op. CF (TTM)

−13.41M

Next earningsNov 18, 2026 →

Latest newsMore news →

No recent news for CNSP.

Similar companies

Soligenix, Inc.SNGX Traws Pharma, Inc.TRAW Cuprina Holdings (Cayman) Limited Class A Ordinary SharesCUPR Evogene Ltd.EVGN Skye Bioscience, Inc.SKYE Exicure, Inc.XCUR Find similar companies →

Latest newsMore news →

No recent news for CNSP.